Kornimate/medical-research-clean huggingface dataset:
registry measuring the impact of adding rna expression testing on referral decisions in early stage lung cancer patients and assessing the disease-free survival with long-term follow-up

Conditions: Lung Cancer; NSCLC; Lung Adenocarcinoma

Summary: this registry is intended to measure the effect of myplan lung cancer™ test has on treatment decisions of surgeons when added to standard clinical-pathological parameters in patients with early stage nsclc.the sponsor is conducting two parallel registries, with one directed at surgeons (onc003) and the other at oncologists (onc006).this registry is specific to surgeons (onc003). outcomes measures on lung cancer relapse and death from any cause will be collected.


Eligibility criteria:
inclusion criteria: * diagnosis of early stage non-small cell lung adenocarcinoma * sub-population staging (ia, ib or iia) as judged by the standard of practice at the investigational site * resection of tumor within previous 2 months of enrollment * ecog performance of 0-2 * a minimum life expectancy of six months exclusion criteria: * pre-operative radiation or chemotherapy for nsclc * post-operative radiation or chemotherapy for nsclc * enrollment in a separate clinical trial restricting treatment options * unable to provide informed consent

Keywords: registry
melatonin gel as an adjuvant in the surgical management of intrabony defects

Conditions: Periodontal Disease, AVDC Stage 3

Summary: surgical periodontal therapy is a commonly employed treatment approach aimed at arresting disease progression and promoting tissue regeneration. despite advancements in surgical techniques, adjunctive therapies are being explored to enhance the outcomes of periodontal surgical debridement. melatonin, a hormone primarily known for its role in regulating the sleep-wake cycle, has emerged as a promising candidate for periodontal therapy. it possesses potent antioxidant, anti-inflammatory, and immunomodulatory properties, which make it an attractive therapeutic agent for treating periodontitis. additionally, melatonin has been linked to bone metabolism, with evidence suggesting its involvement in bone formation and remodeling processes. bone regeneration is a vital aspect of periodontal therapy, as the restoration of lost osseous structures is crucial for long-term stability of affected teeth. previous studies have suggested that melatonin may exert positive effects on bone formation by promoting osteoblast differentiation, stimulating matrix synthesis, and inhibiting osteoclast activity. however, limited research has been conducted to specifically evaluate its influence on bone regeneration in the context of surgical periodontal flap therapy.


Eligibility criteria:
inclusion criteria: 1. both genders within age range of 35-55 years. 2. patients diagnosed with periodontitis stage iii (caton et al., 2018; papapanou et al., 2018). test site criteria: (probing pocket depth ≥6mm and cal ≥5mm and 3-wall intrabondy defect). all these criteria will be determined after phase i conventional periodontal therapy. 3. patients with three-wall intrabony defects. 4. systemically free patients as evidenced by burket's oral health history questionnaire (glick et al., 2008) 5. ability to attend the treatment sessions and comply with the procedures, recall visits and oral hygiene measures. exclusion criteria: 1. smokers. (reynolds et al., 2015) 2. drug abusers. 3. pregnant or lactating females. 4. patients under any medication that affect periodontal healing. 5. vulnerable individuals.

Keywords: stage iii periodontitis melatonin gel xenograft
assessing feasibility of thromboprophylaxis with apixaban in jak2-positive myeloproliferative neoplasm patients

Conditions: Myeloproliferative Neoplasm (MPN); Essential Thrombocythemia (ET); JAK2 Mutation; Polycythemia Vera (PV); Primary Myelofibrosis; Venous Thromboembolism (VTE)

Summary: myeloproliferative neoplasms (mpns) are blood disorders that occur when the body makes too many white or red blood cells, or platelets. this overproduction of blood cells in the bone marrow can create problems for blood flow and lead to various symptoms. one of the major problems is the formation of blood clots. these may form in the veins of a patient's legs or arms where they cause leg or arm pain, swelling or difficulty walking. these clots may travel to the lung and then cause chest pain, shortness of breath and sometimes death. blood clots can also lead to poor or no blood flow to one's heart, brain, or other organs, causing damages that cannot be easily or ever repaired, such as stroke or heart attack. patients diagnosed with certain types of mpn are associated with a higher risk of developing blood clots and related complications. for this reason, mpn patients are usually treated with low-dose aspirin, a common drug used for blood clot prevention, on long-term basis to prevent the formation of blood clots and other complications. however, recent studies also show that the risk of blood clots remains elevated in mpn patients treated with aspirin, and there may not be improvement or reduction in fatal or other events that are associated with blood clots. in addition, since this medical condition is rare, so there's a lack of studies done with high quality results to help physicians decide the best treatment plan for these patients. the study drug, apixaban, is a new type of orally-taken blood thinner that has been shown to be effective and safe for prevention and treatment of blood clots in various patient populations. the investigators will evaluate whether apixaban is safer and/or better at preventing blood clots and other complications in mpn patients compared to aspirin.


Eligibility criteria:
inclusion criteria: 1. male or female subjects aged 18 years or older, 2. confirmed diagnosis of pv, jak2et or jak2 pre-fibrotic mf, per local clinical definitions 3. able and willing to comply with study procedures and follow-up examinations contained within the written consent form exclusion criteria: 1. known allergy to apixaban or aspirin, 2. another need for anticoagulation or specific anti-platelet therapy, 3. contraindication to thromboprophylaxis (which would specifically include but not be limited to platelets less than 50x10\^9/l and acquired von willebrand disease), 4. current pregnancy or breast-feeding, 5. renal dysfunction (creatine clearance \<25 ml/min), 6. known liver disease 7. currently on any medication with a known interaction to apixaban 8. unwilling to use an effective means of contraception for women of childbearing potential 9. overtly fibrotic myelofibrosis 10. myelodysplastic/myeloproliferative neoplasms
immunoevasive tactics employed by myeloid malignancy after allogeneic stem cell transplantation

Conditions: Relapse Leukemia; Allogeneic Stem Cell Transplantation; Immune Evasion, Tumor

Summary: allogeneic hematopoietic stem cell transplantation (allo-hsct) is still the only treatment available to cure acute myeloid leukemia and high risk myelodysplasia. allo-hsct has an anti-tumor effect (called the graft versus leukemia effect= gvl) mediated by donor lymphocytes. this gvl effect is often associated with graft-versus-host disease (gvhd). several studies have shown that the relapse incidence is lower in patients developing chronic gvhd. these studies confirm the impact of donor immune system on leukemic residual cells. in fact, the relapse incidence increased in patients with no sign of gvhd. the investigators assume that leukemic cells probably use mechanisms to inhibit the allogeneic response. these escape mechanisms to immunosurveillance have been described in other malignancies. out of context of the allo-hsct, in acute myeloid leukemias and myelodysplasia, correlations between the severity of the disease and the presence of regulatory t cells (tregs) or exhausted t cells (pd1 positive) in the bone marrow and in the blood of patients were described at the time of diagnosis or relapse. myeloid derived suppressive cells (mdscs) have been described as capable of inducing tregs and exhausted t cells in the tumor microenvironment.the investigators want to evaluate the role of myeloid suppressive cells in bone marrow after allo hsct. they hypothesize that their presence in bone marrow and / or blood recipient is correlated to the relapse incidence.


Eligibility criteria:
inclusion criteria: * patients with acute myeloid leukemia in complete cytological remission with intermediate or high risk prognosis according to eln 2017 * patients with myelodysplasia according to the who 2016 definition, with ipss ≥1.5 and disease status is : stable or in partial response or complete response according to iwg 2006. * patients with indication of first allo-hsct with a matched related or unrelated donor * patients receiving non-myeloablative or reduced toxicity conditioning * patients affiliated to a social security scheme * patients who have received a complete information on the organization of the research and signed his informed consent exclusion criteria: * patients with an alternative donor (hla 5/10 or unit cord blood) * patients with another active cancer or a history of cancer diagnosed in the previous 5 years * patients with uncontrolled infection at the time of inclusion, or with positive hiv (1 + 2) or htlv (1 + 2), hepatitis c or active hepatitis b * patients referred to in articles l. 1121-5, l. 1121-7 and l1121-8 of the public health code.
guided biofilm therapy for periodontal patients.

Conditions: Periodontal Diseases

Summary: periodontal patients will be treated with guided biofilm therapy. at the baseline (t0), the following clinical indices will be collected: bop, bs, cal, ppd. a plaque disclosing agents will be used to instruct the patients to proper oral hygiene procedures. at this stage, using a split-mouth design, quadrants will be randomized to: * airflow and scaling and calculus removal with ems prophylaxis master handpiece * airflow and calculus removal with mectron combi handpiece patients will be visited after 1 month (t1) and 2 months (t2), in which the periodontal indexes will be collected again. after all the procedures, vas for pain will be assessed, with schiff air index, comfort (patients), comfort (operator), timing for the procedures (minutes), satisfaction questionnaire (for patients and for the operator), consumption of the powders for the two handpiece.

periodontal patients that respond to the inclusion criteria and agree to participate in the study will be treated with guided biofilm therapy. at the baseline (t0), the following clinical indices will be collected: bop, bs, cal, ppd. a plaque disclosing agents will be used to instruct the patients to proper oral hygiene procedures. at this stage, using a split-mouth design, quadrants will be randomized to: * airflow and calculus removal with ems prophylaxis master handpiece * airflow and calculus removal with mectron combi handpiece patients will be visited after 1 month (t1) and 2 months (t2), in which the periodontal indexes will be collected again. together with periodontal assessment, vas for pain will be assessed, with schiff air index, comfort (patients), comfort (operator), timing for the procedures (minutes), satisfaction questionnaire (for patients and for the operator), consumption of the powders for the two handpieces.

Eligibility criteria:
inclusion criteria: * professional dental hygiene performed at least 6 months before enrollment * periodontal disease: grading a or b and staging i-iii exclusion criteria: * neurologic, psychiatric and mental diseases * patients taking antibiotics during the study * pregnant and breastfeeding women * patients undergoing anticancer treatment * patients undergoing anticancer therapy

Keywords: guided biofilm therapy
use of buventol easyhaler and bufomix easyhaler in methacoline challenge testing

Conditions: Asthma

Summary: the study compares buventol® easyhaler® and bufomix® easyhaler® to the current standard treatment during methacholine challenge test. the trial will also provide inspiratory flow profile data for easyhaler inhaler. this trial is designed to provide a further evidence for the use of easyhaler in diagnostic bronchial challenge tests and on the use of easyhaler inhaler during obstructive event.


Eligibility criteria:
inclusion criteria: 1. written informed consent (ic) obtained. 2. finnish speaking adult (≥ 18 years old) subject indicated for methacholine challenge test. 3. the subject experiences fev1 drop ≥ 20% compared to post-diluent spirometry. exclusion criteria: 1. subjects not eligible for methacholine challenge test for example for any of the following reasons: * any respiratory infection within 2 weeks, or severe respiratory infection within 4 weeks before the study visit * fev1 \< 60% of predicted or \< 1.0 l * inability to perform acceptable and repeatable spirometry manoeuvres throughout the test procedure * uncontrolled hypertension * acute chest pain or unstable angina pectoris * significant cardiac arrhythmias * pneumothorax or recent bronchoscopy * myocardial infarction or stroke in last 3 months * known aortic aneurysm * recent eye surgery or intracranial pressure elevation risk * cholinesterase inhibitor medication * pregnant or lactating females 2. subjects who have used the following treatments before the study visit: * short-acting β-agonists within 12 h * long-acting β-agonists within 36 h * ultra-long-acting β-agonists within 48 h * long-acting anti-muscarinic agents within 168 h * short-acting anticholinergics within 12 h * oral theophylline within 24 h * inhaled corticosteroids, leukotriene receptor antagonists and chromones within 4 weeks 3. known hypersensitivity to the active substance(s) or the excipients of the study treatments (for example severe milk allergy, lactose contains small amounts of milk protein). 4. administration of another investigational medicinal product within 30 days before the study visit.
effects of rhigf-1 on bone metabolism in adolescent girls with anorexia nervosa

Conditions: Disorder of Bone Density and Structure, Unspecified

Summary: adolescents and young adults with anorexia nervosa (an) are at high risk for low bone mineral density at a time when healthy adolescents are rapidly accruing bone, with implications for peak bone mass and fracture risk in later life. they are also deficient in insulin-like growth factor 1 (igf-1), the bone trophic factor made in the liver in response to growth hormone (gh), despite elevated levels of growth hormone. it is possible that deficiency of insulin-like growth factor 1, a hormone very important for the maintenance of skeletal integrity, may contribute to the severe osteopenia seen in anorexia nervosa. the physiologic effects of recombinant human insulin-like growth factor 1 (rhigf-1) treatment in adolescents and young adults with anorexia nervosa have not been studied. the goal of this proposal is to investigate the effects of recombinant human insulin-like growth factor 1 on bone density and bone microarchitecture in adolescent girls and young adult women with anorexia nervosa over a 6 month period. we hypothesize that adolescent and young adult anorexia nervosa patients, being insulin-like growth factor 1 deficient, will respond to exogenously administered recombinant human insulin-like growth factor 1 with elevations in biochemical indices of bone turnover and an increase in bone density and improvement in bone structure, or maintain bone density (in contrast to the decrease in bone density expected in adolescent girls and women with anorexia nervosa who are not treated).


Eligibility criteria:
inclusion criteria: - meet criteria for anorexia nervosa (an) as described in the diagnostic and statistical manual of mental disorders exclusion criteria: * pregnant or nursing * hematocrit \< 30%, k \< 3 mmol/l * any illness (other than an) known to affect bone and mineral metabolism such as diabetes, untreated hypo- or hyperthyroidism, or hyperparathyroidism * history of use of any medicine, such as corticosteroids, known to affect bone density. subjects who are on estrogen will still be eligible to participate in the study because our data in adult women with an do not indicate deleterious effects of estrogen in patients receiving rhigf-

Keywords: bone density bone turnover markers rhigf-1 bone structure anorexia nervosa
central hemodynamic and sodium urinary

Conditions: Hypertension

Summary: systemic arterial hypertension is one of major risk factors to development of target organ damage that culminate in cardiovascular diseases such as acute myocardial infarction and stroke. sodium intake is related with elevation of arterial blood pressure due to rise of cardiac output and of arterial stiffness and it can be estimated by daily sodium excreted in urine 24h. ambulatory blood pressure monitoring can be used to obtain peripheral and central hemodynamic parameters \[arterial stiffness parameters - central blood pressure, pulse wave velocity and augmentation index\]. applanation tonometry also can be used to check same central hemodynamic parameters. both methods provide us important informations about the patients clinical conditions and help us to infer their prognosis. therefore, this protocol aims measure the central hemodynamic parameters in hypertensive patients, controlled or resistant, and evaluate their sodium urinary excretion. the hypothesis is the resistant hypertensive patients have parameters higher than controlled hypertensive patients.

the urinary sodium (na+) will be evaluated by flame photometry. excretion of urinary sodium will be calculated by multiplying the urinary sodium concentration in me /l by 24-hour urinary volume. two to three urinary na+ samples will be collected within six months. 3.3.3 ablood pressure monitoring - 24 hours ambulatorial blood pressure monitoring 24-hour will be performed using a mobil-o-graph® compact digital device (version 12, ambulatory pressure monitor, 2000, uk). individuals will be instructed to maintain their normal activities of daily living. the device will be pre-programmed to measure blood pressure within 24 hours at 30-minute intervals every hour during the waking period and at 1-hour intervals during sleep. this device will evaluate the following parameters: systolic and peripheral diastolic blood pressure, mean arterial pressure, pulse pressure, systolic central aortic pressure, central diastolic aortic pressure (cdbp), central pulse pressure (cpp), augmentation index corrected for 75 bpm (ai75%) and pulse wave velocity (pwv).

Eligibility criteria:
inclusion criteria: * over than 18 years old; * hypertensive patient for more than four weeks; * controlled hypertension; * resistant hypertension; * regular patient in the local where the study will be done. exclusion criteria: * chronic renal failure in dyalisis; * been in the hospital in last 60 days; * used vasoactive drugs in last 30 days; * heart failure in iii or iv functional class (nyha); * pregnant/breastfeeding; * serious liver disease; * hiv positive; * psychiatric diseases that make it difficult to participate; * stroke or acute myocardial infarction in last 30 days; * cancer with prognosis less than one year.

Keywords: hypertension resistant hypertension arterial stiffness sodium urine test
a study to evaluate the long-term effectiveness of three anti-hiv drug regimens in hiv infected patients who have never been exposed to highly active antiretroviral therapy (haart)

Conditions: HIV Infections

Summary: the purpose of this study is to determine whether it is better to start an anti-hiv regimen containing a protease inhibitor (pi), a non-nucleoside reverse transcriptase inhibitor (nnrti), or a pi in combination with an nnrti. this study will also examine which treatment regimen is best as a first treatment for hiv infection.

highly active antiretroviral therapy (haart) regimens containing pis, nnrtis, or nucleoside reverse transcriptase inhibitors (nrtis) have been shown to slow disease progression. however, the long-term consequences of initial therapy with a pi, an nnrti, or both a pi and an nnrti are not yet known, nor is the impact on future anti-hiv treatment regimens. patients who experience virologic failure on a particular haart regimen typically have not been studied for subsequent response to other haart regimens. it is possible that a regimen which is initially the most potent may not be optimal if it limits the effectiveness of subsequent anti-hiv treatment regimens. patients will be randomized to one of three haart treatment arms: * arm 1 participants will receive one or two pis plus two nrtis. * arm 2 participants will receive one nnrti plus two nrtis. * arm 3 participants will receive one or two pis plus an nnrti plus one or two nrtis. before randomization to a treatment arm, patients will be given the option of preselecting the drugs they will use or allowing randomization to study-specified drugs. the study-specified pis will be indinavir (idv), nelfinavir (nfv), or two pis of patient and doctor choice. the study-specified nnrtis will be nevirapine (nvp) or efavirenz (efv). the study-specified nrtis will be abacavir (abc) plus lamivudine (3tc) or didanosine (ddi) plus stavudine (d4t). the study sites will provide abc, 3tc, ddi, or d4t to all patients who are assigned to take these medications. all other anti-hiv drugs for initial and subsequent treatment regimens are obtained by clinician prescription. at months 1 and 4 and then every 4 months thereafter, patients will receive a medical history update, physical exam, and questionnaire. blood samples will also be drawn to measure cd4 cell count, viral load, and genotypic antiretroviral resistance. changes in treatment regimens may occur at any time.

Eligibility criteria:
inclusion criteria: * hiv infected * agree to practice abstinence or to use barrier methods of birth control during the study * are at least 13 years old or have signed informed consent from legal guardian for patients between the ages of 13 and 18 exclusion criteria: * have ever taken any anti-hiv drugs * are unable to complete the study for any reason * pregnancy * breastfeeding * any condition that, in the investigator's opinion, may interfere with the study

Keywords: drug therapy, combination hiv protease inhibitors reverse transcriptase inhibitors anti-hiv agents treatment naive
leech therapy for postherpetic neuralgia

Conditions: Postherpetic Neuralgia

Summary: the purpose of this study is to investigate, whether leech therapy for the treatment of postherpetic pain improves pain and sensory function. therefore 20 patients with phn undergoing leech therapy at the investigators outpatient clinic will be included in this observational trial.

see above

Eligibility criteria:
inclusion criteria: * 18 to 85 years of age * \>6 months thoracal postherpetic neuralgia * informed consent exclusion criteria: * if leech therapy is contraindicated * physical and mental disability to participate in the study examinations
echocardiographic assessment of intrapulmonary vasodilatation: agitated saline versus polygeline

Conditions: Liver; Cirrhosis

Summary: the purpose of the study is to evaluate agitated saline versus polygeline for detection of intrapulmonary vasodilatation in patients with cirrhosis.

intrapulmonary vasodilatation is a frequent finding in patients with cirrhosis. its diagnosis is established via contrast enhanced echocardiography. one used method is the contrast agent agitated saline and another frequently used method is the contrast agent polygeline. the purpose of this study is to compare these two echocardiographic contrast agents with respect to their ability to detect intrapulmonary vasodilatation.

Eligibility criteria:
inclusion criteria: * age \> 18 years * presence of liver cirrhosis * evaluation for liver transplantation or transjugular intrahepatic portosystemic shunt exclusion criteria: * inadequate echocardiographic image quality * allergies to echocardiographic contrast agents * pulmonary valve stenosis * pulmonary embolism * relevant tricuspid regurgitation * cardiomyopathy

Keywords: liver cirrhosis hepatopulmonary syndrome